Sodium nitroprusside in acute heart failure: A multicenter historic cohort study
| Autor: | Laura Garatti, Simone Frea, Pier Paolo Bocchino, Filippo Angelini, Marco Cingolani, Alice Sacco, Giulia Maria Rondinara, Vincenzo Bagnardi, Isabella Maria Sala, Navin K. Kapur, Paolo C. Colombo, Gaetano, M. De Ferrari, Nuccia Morici |
|---|---|
| Přispěvatelé: | Garatti, L, Frea, S, Bocchino, P, Angelini, F, Cingolani, M, Sacco, A, Rondinara, G, Bagnardi, V, Sala, I, Kapur, N, Colombo, P, De Ferrari, G, Morici, N |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Heart Failure
Nitroprusside History Polymers and Plastics Acute heart failure Stroke Volume Prognosis Industrial and Manufacturing Engineering Peptide Fragments Cohort Studies NT-proBNP Natriuretic Peptide Brain Vasodilator Humans Business and International Management Hypotension Cardiology and Cardiovascular Medicine Sodium nitroprusside Biomarkers Retrospective Studies |
| Popis: | Aims: Despite evidence of hemodynamic benefit of sodium nitroprusside (SNP) treatment for acute heart failure (AHF), there are limited data about its efficacy and safety. This study aimed to assess the effectiveness and safety of SNP treatment, to explore the impact of N-terminal pro-B natriuretic peptide (NT-proBNP) reduction on clinical endpoints and to identify possible predictors of clinical response. Methods and results: Multicenter retrospective cohort study of 200 patients consecutively admitted for AHF in 2 Italian Centers. Primary endpoint was the reduction of NT-proBNP levels ≥25% from baseline values within 48 h from the onset of SNP infusion. Secondary and safety endpoints included all-cause mortality, rehospitalization for HF at 1, 3 and 6 months, length of hospital stay (LOS) and severe hypotension. 131 (66%) patients experienced a NT-proBNP reduction ≥25% within 48 h from treatment onset, irrespective of initial systolic blood pressure (SBP). Left ventricular end diastolic diameter (LVEDD) was the only independent predictor of treatment efficacy. Patients who achieved the primary endpoint (i.e., ‘responders’) had lower LOS (median 15 [IQR:10–27] vs 19 [IQR:12–35] days, p-value = 0.033) and a lower incidence of all-cause mortality and rehospitalization for HF at 1 and 3 months compared to “non responders” (p-value |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|